Approval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation
Novacyt S.A. (AIM: NCYT) Approval of COVID-19 test under CTDA legislation
Paris, France and Camberley, UK – 17 February 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate ® COVID-19 2G
Novacyt S.A. (NCYT.L) Strategy and Full Year 2021 Trading Update
Full-year revenue and EBITDA in line with expectations
Novacyt S.A. (NCYT.L) Half Year Update, Investor meeting at 13:00 BST / 14:00 CEST
Paris, France and Camberley, UK – 18 August 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces a half year update in
Novacyt S.A. (NCYT.L) Full year 2020 results and update on strategy
Transformational performance in 2020 Continued strong demand for COVID-19 testing in 2021
Novacyt S.A. (NCYT.L) DHSC Dispute Update
Paris, France and Camberley, UK – 21 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update to its ongoing dispute with
Novacyt S.A. (NCYT.L) Inclusion of SNPsig in the NHS England Framework
Inclusion of SNPsig® SARS-CoV-2 PCR genotyping portfolio in the NHS England Framework and expansion of SNPsig® product range
Novacyt S.A. (NCYT.L) Novacyt donates 1 million COVID-19 tests to UNICEF
Donation supports testing efforts to help ensure continued access to essential services for children and their families